Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus
- 6 June 2018
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 17 (8), 791-795
- https://doi.org/10.1016/j.autrev.2018.02.010
Abstract
Discoid lupus erythematosus (DLE) is a chronic dermatological disease that can lead to scarring, alopecia and dyspigmentation, if not properly treated. Actually, no drugs are specifically approved for the treatment of CLE, although the first-line therapy usually consists of photoprotection associated to topical or oral steroids, topical calcineurin inhibitors and hydroxychloroquine (HCQ). In cases of DLE refractory to these medications, many other agents have been employed, such as dapsone, methotrexate, azathioprine, cyclophosphamide, biologic drugs and Intravenous Immunoglobulin (IVIG). We described the case of a DLE patient resistant to combination therapy with steroid and HCQ who was successfully treated with cyclical IVIG therapy. The treatment with IVIG resulted rapidly effective with persistent efficacy and low rates of relapses, although more cycles of IVIG are needed to achieve a stable clinical remission. We also discussed the beneficial and promising effects of IVIG in patients with Cutaneous Lupus reporting the previously published data.Keywords
This publication has 23 references indexed in Scilit:
- The classification and diagnosis of cutaneous lupus erythematosusJournal of Autoimmunity, 2014
- Cutaneous lupus erythematosus: Diagnosis and treatmentBest Practice & Research Clinical Rheumatology, 2013
- Intravenous Immune Globulin in Autoimmune and Inflammatory DiseasesNew England Journal of Medicine, 2012
- Cutaneous Lupus ErythematosusAmerican Journal of Clinical Dermatology, 2009
- Evidence for the Use of Intravenous Immunoglobulins—A Review of the LiteratureClinical Reviews in Allergy & Immunology, 2009
- Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternativeClinical Rheumatology, 2006
- IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patientsAutoimmunity, 2005
- Intravenous immunoglobulin (IVIg) for therapy‐resistant cutaneous lupus erythematosus (LE)Journal of Dermatological Treatment, 2004
- High-Dose Intravenous Immunoglobulin in Cutaneous Lupus ErythematosusArchives of Dermatology, 1999
- Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosusLupus, 1997